Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Accumulated Depreciation (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed Accumulated Depreciation for 3 consecutive years, with $8.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Accumulated Depreciation rose 42.78% to $8.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $8.5 million, a 42.78% increase, with the full-year FY2025 number at $8.5 million, up 42.78% from a year prior.
  • Accumulated Depreciation was $8.5 million for Q4 2025 at Artiva Biotherapeutics, up from $7.2 million in the prior quarter.
  • In the past five years, Accumulated Depreciation ranged from a high of $8.5 million in Q4 2025 to a low of $3.5 million in Q4 2023.
  • A 3-year average of $6.3 million and a median of $6.5 million in 2025 define the central range for Accumulated Depreciation.
  • Peak YoY movement for Accumulated Depreciation: soared 67.7% in 2024, then skyrocketed 42.78% in 2025.
  • Artiva Biotherapeutics' Accumulated Depreciation stood at $3.5 million in 2023, then skyrocketed by 67.7% to $5.9 million in 2024, then soared by 42.78% to $8.5 million in 2025.
  • Per Business Quant, the three most recent readings for ARTV's Accumulated Depreciation are $8.5 million (Q4 2025), $7.2 million (Q2 2025), and $6.5 million (Q1 2025).